Business & Practice Management

Health Technology

Interpersonal Communications

Medical Ethics

Professional Development

Public Health & Health Policy

Women in Medicine

Family Life

General Personal Interests

Mental Health & Wellness

Personal Finance

Chronic Migraine

Mary can't find relief from her migraines—Can you help?

B-ALL 

Case challenge: Can you get this pediatric ALL patient’s treatment back on track?

Gallbladder Cancer

Case challenge: What's best for this stage 4b gallbladder cancer patient?

ES-SCLC Side Effects

Mitigating ES-SCLC treatment side effects with Dr. Misty Shields

ES-SCLC Diagnosis

Navigating the diagnostic steps of ES-SCLC with Dr. Misty Shields

ES-SCLC Toxicity 

On the front lines: Managing toxicity in ES-SCLC with Dr. Jared Weiss

Uncontrolled Asthma

Your patient has uncontrolled asthma—how do you assess for biologics treatment?

Alzheimer's Disease

Addressing a 76-year-old patient's memory loss 

Lennox-Gastaut Syndrome

Does this 5-year-old have Lennox-Gastaut syndrome?

Adult ALL

Jenny's C10403 regimen doesn't go according to plan. Can you get it back on track?

AHS 2026: What's Shaping the Future of Migraine Care

Real Talk

Patient Perspectives

Residency Roadmap

Medical Hot Potatoes

Wellness Matters

Malpractice Monitor

Beyond the white coat: Physician side gigs

The legal battlefield of medicine: Medical malpractice

The Physician Unionization Trend 2023

Seventies Flashback: Doctors Then vs Now

Physician Compensation 2023

AI in Oncology

Controversies in Rheumatology

Violence Against HCPs

Innovative Oncology

Post-Residency Preparedness

Physician Shortage

Mental Health

Substance Abuse

Allergy & Immunology

Anesthesiology

Cardiology

Critical Care

Dermatology

Emergency Medicine

Endocrinology

Family Medicine

Gastroenterology

Genetics

Infectious Disease

Internal Medicine

Nephrology & Urology

Neurology

Obstetrics & Gynecology

Oncology & Hematology

Ophthalmology

Orthopedics

Otolaryngology & Dental Medicine

Pain Medicine

Pediatrics

Pharmacy

Psychiatry

Pulmonology

Radiology

Rheumatology

Surgery

"Ozempic Personality" What is it?

"I saw a psychiatrist on X saying the new executive order could speed up psychedelic research, and another post said clinicians shouldn’t dismiss patients who ask about it. I’ve been stuck for years, so I want to know: Is psilocybin actually a real option for me now?"

I saw that psychedelics are being fast-tracked for depression. I’ve tried antidepressants before, and I’m wondering if this is finally something that could help me.

The patient leans forward, visibly relieved

"I get why you’re excited—there’s a lot of buzz on psychedelics right now. But the research is still in early stages, and the executive order speeds studies, not approvals. Let’s focus on evidence-based options first, and we can revisit this conversation once we know more."

Collaborate on a shared plan: Offer to review approved options first (optimized antidepressants, psychotherapy like CBT, lifestyle interventions) before escalating. Frame psychedelics as a potential future or adjunct option for resistant cases, not a shortcut. This matches APA guidance: Inadequate evidence for routine endorsement outside approved investigational studies. 


The patient furrows their brow, looking uncertain

“I hear you, but here’s where the data stands: Early trials show psilocybin-assisted therapy can produce rapid reductions in depression scores for some, but we still lack large phase 3 trials with long-term follow-up. Risks include potential worsening of psychosis or anxiety. Bottom line: Promising, but not ready for patients.”


Anchor the discussion in shared decision-making, clarify the difference between research and approval, and contextualize both benefits and risks in plain language. Physicians should emphasize that most evidence comes from small, controlled phase 2 trials with psychological support, and that long-term safety and real-world effectiveness remain uncertain.

The patient crosses their arms and pulls back

“Social media hype is running way ahead of the science. We have decades of data on antidepressants and therapy that actually work for most people. Psychedelics? The evidence is still thin, the risks are real, and the loudest voices pushing this have zero clinical experience.”


De-escalate & re-engage: Acknowledge frustration (“I hear you’re desperate for relief”), reaffirm openness to evidence-based discussion, then pivot to "Let’s focus on what’s proven while we monitor new data."

Psychedelic Hype, Exam Room Reality

Welcome Back. 

acquisition_returning_user